| 1 |
34030643 | Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). | 2021 May 24 |
1 |
| 2 |
34039959 | BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. | 2021 May 26 |
2 |
| 3 |
32086346 | Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. | 2020 Jun 1 |
2 |
| 4 |
30940721 | Maintenance Rucaparib Controls Some Pancreatic Cancers. | 2019 Jun |
1 |
| 5 |
27702817 | Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib. | 2017 Apr 15 |
1 |
| 6 |
28057616 | Rucaparib Approved for Ovarian Cancer. | 2017 Feb |
1 |
| 7 |
28264872 | A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors. | 2017 Aug 1 |
2 |
| 8 |
28588062 | Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. | 2017 Sep |
1 |
| 9 |
26438157 | Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. | 2015 Dec |
1 |
| 10 |
24632590 | Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. | 2014 May 30 |
1 |
| 11 |
25558828 | A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. | 2014 |
1 |